WHO and Partners Will Organize Large International Study for Robust COVID-19 Data

News
Article

In a daily press briefing on March 18, 2020, the World Health Organization (WHO) announced that, along with its partners, it will be organizing a large international study that will compare various untested treatments for COVID-19.

In a daily press briefing on March 18, 2020, the World Health Organization (WHO) announced that, along with its partners, it will be organizing a large international study that will compare various untested treatments for COVID-19.

The Solidarity Trial has been designed to generate sufficient data so that it will be possible to find the treatments that are most effective at treating COVID-19. Additionally, in the briefing, it was revealed that the procedures for the trial have been simplified so that hospitals, which are currently dealing with a large influx of work, can participate.

Countries that have already confirmed participation in the Solidarity Trial are Argentina, Bahrain, Canada, France, Iran, Norway, South Africa, Spain, Switzerland, and Thailand. Funding for the trial has reached US$43 million already, which has been received from over 173,000 individuals and organizations.

Source: WHO

 

Recent Videos
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Related Content